Reports Q4 revenue $121,000, consensus $1.46M. “The enthusiasm for barzolvolimab continues to build, driven by unparalleled efficacy data across multiple indications,” said Anthony Marucci, co-founder, president and CEO of Celldex (CLDX). “This is underscored by the completion of enrollment in our Phase 3 CSU studies six months ahead of guidance and strong interest from clinical trial sites in our recently initiated Phase 3 study in cold urticaria and symptomatic dermographism.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex completes enrollment in Phase 3 studies of barzolvolimab
- Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
- Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
- Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch